PAVmed

PAVmed reported an attributable GAAP net loss of $5.5 million ($0.87 per share) for Q2 2026 versus $12.3 million a year earlier, and a non‑GAAP loss of $1.7 million. The company is advancing development and commercialization initiatives for Lucid Diagnostics, Veris, PortIO and Octeris and sees a possible 510(k) regulatory pathway for PortIO. Cash and cash equivalents were $3.8 million as of June 30; management stresses progress but financing and reimbursement risks remain. The stock fell to $4.61 after the results and is trading near its 52‑week low. » Altro su de.investing.com

PAVmed reported a GAAP net loss of $1.1 million for Q1 2026 but completed a two‑year restructuring that eliminated convertible preferred stock and debt instruments. The shares rose 3.1% premarket to $6.65 as investors welcomed the simplified capital structure and progress at Veris Health and Lucid Diagnostics. The company holds $6.5 million in cash, expects potential Medicare reimbursement for Lucid, and plans an FDA filing for an implantable Veris monitor by the end of 2026. » Altro su de.investing.com

PAVmed appoints Joseph Virgilio as senior vice president and chief business officer, Medical Devices, and simultaneously names him CEO of PortIO Inc. and of newly founded subsidiary Octeris, which will advance an endoscopic imaging technology for the esophagus licensed from Duke University. The company consolidates its revamped medical device portfolio, including the implantable PortIO system, while pursuing additional opportunities in gastroesophageal reflux technologies. Financials show a strained position: market capitalization about $196 million, revenue of $4.7 million in the last twelve months, and ongoing losses with strong cash burn. » Altro su de.investing.com